advanced multiple tumors
Conditions
Interventions
Observation group:None
Sponsors
Sun Yat-sen University Cancer Prevention Center(YNMT)·
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion Criteria Phase I The inclusion criteria include: 1) >= 18 years of age at diagnosis. 2) Having a pathologically (histologically or cytologically) confirmed advanced multiple tumors that is incurable and for which prior standard first-line treatment has failed. 3) Tumors diagnosed from November 2021 to June 2024. 4) Available medical history document. Phase II The inclusion criteria include: 1) >= 18 years of age at diagnosis. 2) Confirmed diagnosis of advanced multiple tumors. 3) With record of MSI-H/dMMR. All inclusion and exclusion criteria will be reviewed by the investigator or qualified designee to ensure that the subject qualifies for the study.
Exclusion criteria
Exclusion criteria: Exclusion Criteria The patients will be excluded if: 1) medical records are incomplete (missing data>30%), 2) having other concurrent malignancy, 3) MSI/MMR result reported by NGS only, 4) had a diagnosis of immunodeficiency or an active autoimmune disease or had received immunosuppressive therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of this study is to describe the real-world MSI/MMR testing pattern in 2L/2L+ treatment of patients with advanced multiple tumors in China.;The rate of MSI/MMR testing (%): calculate and rank the MSI/MMR testing rate by tumor type;Timing of the testing in the course of diseases;Sample sources (count with percentage);Methods and platform of testing (count with percentage for IHC/PCR);The number and sequence of biomarkers co-tested;Information of any other biomarker testing status (count); | — |
Secondary
| Measure | Time frame |
|---|---|
| the present study refer to the detailed treatment pattern of patients with MSI-H/dMMR for the 2L/2L+ treatment setting in the three tumor types in China;Treatment options of 2L/2L+ in patients based on MSI-H/dMMR;The treatment setting in previous line; | — |
Countries
China
Contacts
Public ContactYunjing Ping
Sun Yat-sen University Cancer Prevention Center(YNMT)·
Outcome results
None listed